Cargando…

Simvastatin in the Treatment of Colorectal Cancer: A Review

Drug repositioning and drug reuse are the heated topics in the field of oncology in recent years. These two concepts refer to seeking effective drugs for cancer that are not originally intended to treat cancer. The survival benefits are then analyzed by combining the re-positioned drugs with convent...

Descripción completa

Detalles Bibliográficos
Autores principales: Zang, Hongliang, Yang, Wei, Tian, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303163/
https://www.ncbi.nlm.nih.gov/pubmed/35873646
http://dx.doi.org/10.1155/2022/3827933
_version_ 1784751794921930752
author Zang, Hongliang
Yang, Wei
Tian, Xiaofeng
author_facet Zang, Hongliang
Yang, Wei
Tian, Xiaofeng
author_sort Zang, Hongliang
collection PubMed
description Drug repositioning and drug reuse are the heated topics in the field of oncology in recent years. These two concepts refer to seeking effective drugs for cancer that are not originally intended to treat cancer. The survival benefits are then analyzed by combining the re-positioned drugs with conventional cancer treatment methods. Simvastatin is a clinically commonly used hyperlipidemia drug and exerts the effect of preventing cardiovascular diseases. Recent studies have found that simvastatin has great potential in the treatment of colorectal cancer, and a large number of clinical studies have used simvastatin as an adjuvant drug to help treat metastatic colorectal cancer.
format Online
Article
Text
id pubmed-9303163
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-93031632022-07-22 Simvastatin in the Treatment of Colorectal Cancer: A Review Zang, Hongliang Yang, Wei Tian, Xiaofeng Evid Based Complement Alternat Med Review Article Drug repositioning and drug reuse are the heated topics in the field of oncology in recent years. These two concepts refer to seeking effective drugs for cancer that are not originally intended to treat cancer. The survival benefits are then analyzed by combining the re-positioned drugs with conventional cancer treatment methods. Simvastatin is a clinically commonly used hyperlipidemia drug and exerts the effect of preventing cardiovascular diseases. Recent studies have found that simvastatin has great potential in the treatment of colorectal cancer, and a large number of clinical studies have used simvastatin as an adjuvant drug to help treat metastatic colorectal cancer. Hindawi 2022-07-14 /pmc/articles/PMC9303163/ /pubmed/35873646 http://dx.doi.org/10.1155/2022/3827933 Text en Copyright © 2022 Hongliang Zang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Zang, Hongliang
Yang, Wei
Tian, Xiaofeng
Simvastatin in the Treatment of Colorectal Cancer: A Review
title Simvastatin in the Treatment of Colorectal Cancer: A Review
title_full Simvastatin in the Treatment of Colorectal Cancer: A Review
title_fullStr Simvastatin in the Treatment of Colorectal Cancer: A Review
title_full_unstemmed Simvastatin in the Treatment of Colorectal Cancer: A Review
title_short Simvastatin in the Treatment of Colorectal Cancer: A Review
title_sort simvastatin in the treatment of colorectal cancer: a review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303163/
https://www.ncbi.nlm.nih.gov/pubmed/35873646
http://dx.doi.org/10.1155/2022/3827933
work_keys_str_mv AT zanghongliang simvastatininthetreatmentofcolorectalcancerareview
AT yangwei simvastatininthetreatmentofcolorectalcancerareview
AT tianxiaofeng simvastatininthetreatmentofcolorectalcancerareview